Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 5, 1999, Pages 395-402

  Mirsalis, Jon C ^a   Schindler Horvat, Janice ^a   Hill, James R ^a   Tomaszewski, Joseph E ^b   Donohue, Susan J ^b   Tyson, Charles A ^a  

^a SRI INTERNATIONAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer chemotherapy; Dolastatin 10; Myelotoxicity; Preclinical toxicology

Indexed keywords

DOLASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG ISOLATION; EXTRAMEDULLARY HEMATOPOIESIS; GROWTH INHIBITION; HISTOPATHOLOGY; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; RAT; TARGET CELL;

ANEMIA; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; DOGS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; INJECTIONS, INTRAVENOUS; LEUKOCYTE COUNT; MALE; MICE; MICE, INBRED STRAINS; OLIGOPEPTIDES; RATS; RATS, INBRED F344; RETICULOCYTE COUNT; WEIGHT GAIN; WEIGHT LOSS;

EID: 0032859305     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050995     Document Type: Article

References (21)

1. 1. Aherne GW, Hardcastle A, Valenti M, Bryant A, Rogers P, Pettit GR, Srirangam JK, Kelland LR (1996) Antitumor evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Cancer Chemother Pharmacol 38: 225
2. 2. Bai R, Pettit GR, Hamel E (1990) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39: 1941
3. 3. Bai R, Pettit GR, Hamel E (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265: 17141
4. 4. Battafarano DF, Zimmerman GC, Older SA, Keeling JH, Burris HA (1995) Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 76: 110
5. 5. Beckwith M, Urba WJ, Longo DL (1993) Growth inhibition of human lymphoma cell lines by the marine products dolastatins 10 and 15. J Natl Cancer Inst 85: 483
6. 6. Carrato A, Rosell R, Camps C, Anton A, Garcia-Gomez R, Aranda E, Massuti B, Diaz-Fernandez N, Sanchez JJ, Garcia-Paredes ML (1997) Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. Lung Cancer 17: 261
7. 7. Dorr RT, Jones SE (1979) Inapparent infiltrations associated with vindesine administration. Med Pediatr Oncol 6: 285
8. 8. Gopinath C, Prentice DE, Lewis DJ (1987) Atlas of experimental toxicological pathology, vol 13. MTP Press, Boston, p 131
9. 9. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JK, Tormey DC, Swaminathan S, Trump DL (1987) Phase I study of Taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 71: 1179
10. 10. Jacobsen SEW, Ruscetti FW, Longo DL, Keller JR (1991) Antineoplastic dolastatins: potent inhibitors of hematopoietic progenitor cells. J Natl Cancer Inst 83: 1672
11. 11. Kris MG, O'Connell JP, Gralla RJ, Wertheim MS, Parente RM, Schiff PB, Young CW (1986) Phase I trial of Taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70: 605
12. 12. Maki A, Mohammad R, Raza S, Saleh M, Govindaraju KD, Pettit GR, Al-Katib A (1996) Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines. Anticancer Drugs 7: 344
13. 13. McElroy EA Jr, Pitot HC, Erlichman C, Reid JM, Ames MM, Windebank AJ, Sloan JA, Rubin J (1997) Phase I trial of dolastatin 10 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 16: 223a
14. 14. Newman RA, Fuentes A, Covey JM, Benvenuto JA (1994) Preclinical pharmacology of the natural marine product dolastatin 10 (NSC 376128). Drug Metab Dispos 22: 428
15. 15. Parchment RE, Huang M, Erickson-Miller CL (1993) Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol 21: 241
16. 16. Parchment RE, Volpe DA, LoRusso PM, Erickson-Miller CL, Huang M, Murphy MJ, Grieshaber CK (1994) In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD 115934) to myeloid and erythroid hematopoietic progenitors from human, murine and canine marrow. J Natl Cancer Inst 86: 273
17. 17. Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyi L, Tomer KB, Bontems RJ (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 109: 6883
18. 18. Reid JM, Walker DL, Ames MM (1995) Evaluation of an L1210 bioassay and HPLC for determination of dolastatin 10 in human and murine plasma. Proc Am Assoc Cancer Res 36: 364
19. 19. Stein RS, Roth DG (1976) Myelotoxicity of vincristine-prednisone therapy in treatment of chronic myelogenous leukemia in blastic transformation. Am J Hematol 1: 387
20. 20. Tomaszewski JE, Smith AC (1997) Safety testing of antitumor agents. In: Williams PD, Hottendorf GH (eds) Comprehensive toxicology, toxicity testing and evaluation, vol 2. Elsevier Science, Oxford, p 299
21. 21. Yap HY, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL (1980) Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64: 279